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Background: Previous studies have shown that 5-HT3-antagonists reduce muscle pain, but there are no studies that
have investigated the expression of 5-HT3-receptors in human muscles. Also, tetrodotoxin resistant voltage gated
sodium-channels (NaV) are involved in peripheral sensitization and found in trigeminal ganglion neurons innervating
the rat masseter muscle. This study aimed to investigate the frequency of nerve fibers that express 5-HT3A-receptors
alone and in combination with NaV1.8 sodium-channels in human muscles and to compare it between healthy
pain-free men and women, the pain-free masseter and tibialis anterior muscles, and patients with myofascial
temporomandibular disorders (TMD) and pain-free controls.
Methods: Three microbiopsies were obtained from the most bulky part of the tibialis and masseter muscles of
seven and six healthy men and seven and six age-matched healthy women, respectively, while traditional open
biopsies were obtained from the most painful spot of the masseter of five female patients and from a similar
region of the masseter muscle of five healthy, age-matched women. The biopsies were processed by routine
immunohistochemical methods. The biopsy sections were incubated with monoclonal antibodies against the
specific axonal marker PGP 9.5, and polyclonal antibodies against the 5-HT3A-receptors and NaV1.8 sodium-channels.
Results: A similar percentage of nerve fibers in the healthy masseter (85.2%) and tibialis (88.7%) muscles expressed
5-HT3A-receptors. The expression of NaV1.8 by 5-HT3A positive nerve fibers associated with connective tissue was
significantly higher than nerve fibers associated with myocytes (P < .001). In the patients, significantly more fibers per
section were found with an average of 3.8 ± 3 fibers per section in the masseter muscle compared to 2.7 ± 0.2 in the
healthy controls (P = .024). Further, the frequency of nerve fibers that co-expressed NaV1.8 and 5-HT3A receptors was
significantly higher in patients (42.6%) compared to healthy controls (12.0%) (P < .001).
Conclusions: This study showed that the 5-HT3A-receptor is highly expressed in human masseter and tibialis muscles
and that there are more nerve fibers that express 5-HT3A-receptors in the masseter of women with myofascial TMD
compared to healthy women. These findings indicate that 5-HT3-receptors might be up-regulated in myofascial TMD
and could serve as potential biomarkers of chronic muscle pain.
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Serotonin (5-HT) is an important biogenic amine that
fulfills the role of a neurotransmitter and neuromodula-
tor, and is an important mediator of pain both peripher-
ally and centrally [1,2]. Several studies have shown that
5-HT concentrations are significantly elevated in painful
muscles of patients with chronic myalgia [3-6]. In the
periphery, 5-HT has been shown to excite and sensitize
nociceptors, and in humans to cause muscle pain and
sensitivity [7]. Excitation of nociceptors by 5-HT may be
due to either a direct effect, such as activation of the 5-
HT3 receptor, or an indirect effect, which may involve
the release of other algogens, such as substance P or glu-
tamate [8,9]. In humans, evidence suggests that 5-HT ac-
tivates the 5-HT3-receptor to mediate muscle pain and
sensitivity to mechanical stimulation [7,10-14].
Five subunits of the 5-HT3-receptor have been identi-
fied (5-HT3A – 5-HT3E). The 5-HT3A subunit forms a
complete receptor, while the other subunits can only
form functional receptor complexes together with the 5-
HT3A subunit [15-17]. Results from some studies indi-
cate that intramuscular injections of 5-HT3 antagonists
may be effective for treatment of various muscular pain
conditions [18-20]. The 5-HT3 antagonist granisetron
has been shown to reduce pain and allodynia induced by
5-HT or hypertonic saline [10,13] and also to increase
the pressure pain threshold (PPT) over healthy muscles
in human experimental studies [10,11,21]. In a recent
study, we reported that approximately 45-50% of the
muscle nerve fibers of both healthy humans and rat
expressed the NMDA receptor subunit 2B [22] but the
expression of 5-HT3-receptors in human muscles has
not yet been investigated nor if the frequency is altered
in painful muscles. Hence, it is not clear if the pain-
reducing effect of these 5-HT3 antagonists is only due to
blocking of 5-HT3 receptors or if they act on other re-
ceptors as well.
The tetrodotoxin (TTX) resistant sodium channels
(NaVs) have been shown to be highly expressed in small
neurons of the dorsal root ganglia (DRG) in both human
and animal studies considered to be probable nocicep-
tors [23]. The NaV1.8 channel has also been found in the
soma of small diameter sensory C and Aδ neurons [24]
which have been shown to be involved in nociception in
models of neuropathic and inflammatory pain [25]. One
study reported that the NaV1.8 channel is present in 86%
of the muscle sensory afferent fibers, which makes it a
useful marker of putative muscle nociceptors [26], and
recently it has been found in trigeminal ganglion neu-
rons innervating the rat masseter muscle [27]. Taken to-
gether, this evidence suggests that NaV1.8 channel mainly
found in the peripheral sensory neurons and their expres-
sion on nerve fibers provides a method to identify puta-
tively nociceptive afferent fibers [24,28]. The NaV1.8 hasbeen shown to participate in nociception and peripheral
sensitization, and therefore is thought to be an important
for chronic pain [23-25,29,30]. It has further been shown
that inflammatory mediators, such as serotonin, increase
the excitability of sensory neurons by modulating the
NaV1.8 [31-33]. Therefore, NaV1.8 is particularly interest-
ing both as a marker of putative nociceptive afferent fibers
and as an additional target/mechanism to explain the an-
algesic effects of local administration of the 5-HT3 recep-
tor antagonists [10,18-21].
The purpose of this study was to investigate the ex-
pression of 5-HT3A-receptors and NaV1.8 sodium chan-
nels in nerve fibers of human masseter and tibialis
muscles, since results from both animal and human ex-
perimental studies suggest that 5-HT3 receptor antago-
nists reduce musculoskeletal pain and hyperalgesia
[18-20]. Further, it is not known if the 5-HT3 receptor is
expressed in painful muscle tissues of humans. If so, it
could offer an important target for novel treatment ap-
proaches for these patients and provide important informa-
tion about the pathophysiology of muscle pain especially in
the temporomandibular region. Therefore, the study also
aimed to investigate the frequency of nerve fibers that co-
express the 5-HT3A-receptors and NaV1.8 sodium channels
and to compare the frequency 1) between healthy pain-free
men and women; 2) between patients with myofascial tem-
poromandibular disorders (TMD) and pain-free, healthy,
sex- and age-matched controls; and 3) between the mas-
seter and tibialis anterior muscles (a muscle seldom af-
fected by chronic pain) of healthy men and women. An
additional aim of the study was to investigate if a minimal
invasive microbiopsy technique is equivalent to the trad-
itional open biopsy technique for immunohistochemical
analyses of receptor expression in human muscles.
Methods
The methods and selection of participants were approved
by the regional ethical review board in Stockholm,
Sweden, (2007/2:6). All participants were above 20 years
of age and the study followed the principles for medical
research according to the guidelines of the Declaration of
Helsinki as well as the Good Clinical Practice guidelines.
At a separate visit the participants were screened for
trial suitability with a clinical examination performed in
accordance with the Research Diagnostic Criteria for
TMD (RDC/TMD [34]) after information about the
study protocol. The participants received both written as
well as verbal information and gave their verbal and
written consent.
Participants
Twenty three healthy volunteers and five patients with
myofascial TMD were included in the study. The pa-
tients were recruited from patients referred to the
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of Dental Medicine, Karolinska Institutet, Huddinge,
Sweden, while the healthy volunteers were recruited
from colleagues at the Department of Dental Medicine.
The biopsy procedure took place at the Department of
Dental Medicine, Karolinska Institutet, Huddinge, Sweden
at the section for Orofacial Pain and Jaw Function as well
as at the section of Oral and Maxillofacial Surgery.
The distribution of the participants, their age and the
duration of the local pain are shown in Table 1.
Inclusion criteria
The inclusion criteria for the healthy volunteers were
age over 20 years and good general health.
The inclusion criteria for the patients were age over
20 years, a diagnosis of myofascial pain according to
RDC/TMD criteria and pain, upon digital palpation, of
at least one of the masseter muscles.
Exclusion criteria
The exclusion criteria for both the healthy volunteers
and the patients were diagnosis of: a) systemic muscular
or joint diseases (e.g. fibromyalgia, rheumatoid arthritis,
ankylosing spondylitis, psoriatic arthritis); b) whiplash as-
sociated disorder; c) neuropathic pain or neurological dis-
orders (e.g. myasthenia gravis, craniomandibular dystonia),Table 1 The distribution of the age-matched participants divi
Microbiopsy
Healthy -Masseter H
Number of participants
All 12
Men 6
Women 6
Age
All 34.6 (±10.1)
Men 34.8 (±9.9)
Women 34.3 (±11.2)
Duration of pain
Men
Women
Intensity of pain
Men
Women
Co-morbid headache
Men
Women
The table displays the number (n) of participants, their mean (±SD) age (years), med
as well as number (n) of patients with co-morbid headache. The 12 participants in t
14 in the tibialis group.
NRS = Numeric rating scale (0–10).
IQR = Interquartile range (75 percentile minus 25 percentile).or report of: d) pain of dental origin; e) pregnancy; f) fre-
quent use of muscle relaxants; and g) use of analgesic or
anti-inflammatory medication during the 24 hours preced-
ing biopsy.
An additional exclusion criterion for the healthy vol-
unteers was facial pain or palpatory tenderness of the
masseter or tibialis muscles.
Biopsy-procedures
Microbiopsies
Microbiopsies were obtained from the masseter and tibi-
alis anterior muscles from seven healthy men and seven
age-matched healthy women. During the analysis process
two biopsies from the masseter muscle were misplaced
(from one man and one woman). The microbiopsies were
taken through the skin overlaying the most prominent
part of the masseter muscle and the tibialis anterior
muscle. This procedure was performed under skin surface
anesthesia using a prefabricated anesthetic patch (EMLA
Patch®, 25 mg lidocaine and 25 mg prilocaine, AstraZe-
neca, Södertälje, Sweden) that was placed over the area to
be penetrated, for a duration of 30 min. A disposable
Monopty®Bard® biopsy instrument with a penetration
depth of 11 mm and a diameter of 18G was used for the
masseter muscle, while for the tibialis anterior muscle a
diameter of 16G was used. The biopsy instrument wasded by biopsy technique and sex
Traditional open biopsy
ealthy - Tibialis Healthy Patients
14 5 5
7 0 0
7 5 5
37.4 (±11.8) 52.0 (±8.5) 50.4 (±8.2)
37.7 (±11.9) - -
37.1 (±12.6) 52.0 (±8.5) 50.4 (±8.2)
-
3.0 (±2.6)
-
5.0 (±1.25)
-
5
ian (IQR) duration of pain (years), current median (IQR) intensity of pain (NRS),
he microbiopsy masseter group are the same individuals as the 12 out of the
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den, Helsingborg, Sweden), that was inserted to a depth of
10 mm. This biopsy system is automated and of a type
that has been proven to be effective i.e. for the diagnosis
of musculoskeletal sarcomas [35].
Three microbiopsies were taken from each muscle in
order to ensure that sufficient muscle tissue was ob-
tained. The coaxial needle was inserted along the near
long axis of the muscles until the fascia was penetrated
and the biopsy instrument was then inserted through
the coaxial needle. By pressing the trigger button the
piston of the needle collected a piece of the muscle with
a size of approximately 0.12 cm * 1.1 cm in the masseter
and 0.14 cm * 1.1 cm in the tibialis anterior. The biopsy
instrument was then slid out from the coaxial needle
while the latter was maintained in place, thus avoiding
repeated skin punctures. The muscle section was re-
moved from the biopsy instrument using a sterile probe,
and the biopsy instrument was rinsed with isotonic saline.
This procedure was repeated twice. Each time the biopsy
instrument was rotated 45° so that the microbiopsy would
be taken from a new portion of the muscle.
Traditional open biopsies
Traditional open biopsies were obtained intra-orally
from the masseter muscle of five myofascial TMD pa-
tients (all women) and from five healthy, age-matched
women (not participating in the microbiopsy part). In
the patients the most painful spot of the masseter
muscle was aimed at, while in the healthy volunteers the
spot selected coincided with the most painful spot in the
patient that they were to be compared with.
After anesthesia with 1 mL lidocaine-adrenalin
(20 mg/mL + 12.5 μg/mL) the oral mucosa was incised
with a scalpel to expose the masseter muscle. The se-
lected section was then cut out and removed from the
muscle with a forceps. Two vicryl-sutures were placed
over the incision and removed after one week.
The biopsies from the healthy volunteers were also
used to validate the minimal invasive microbiopsy tech-
nique. This was done by investigating if the muscle sec-
tions obtained with the two different techniques were
equivalent regarding the weight and size of the obtained
biopsies, the amount of surrounding tissue in the biopsies,
receptor expression, the subjective post-surgical discom-
fort and the participants’ experience of the procedures as
well as the area of the wound.
Analysis of the biopsies
Blinding of samples
The microbiopsies were obtained and coded by NC (DDS,
PhD, specialist in orofacial pain and jaw function), the hu-
man traditional open biopsies were obtained by AR (DDS,
PhD, Professor, specialist in oral and maxillofacial surgery)and coded by NC. The codes were not revealed to the per-
son (IK) analyzing the samples.Immunohistochemistry
Both the microbiopsies and the open biopsies were fixed
with 4% paraformaldehyde at 4°C over-night, rinsed in
phosphate-buffered saline (PBS), and then dehydrated,
embedded in paraffin and sectioned at a thickness of
10 μm. The sections were mounted on glass slides,
stored at 37°C over-night, dipped into xylene to remove
the paraffin and rehydrated by being rinsed in ethanol
(100%, 90% and 70%). The sections were then boiled in
10 mM (pH 6.0) citrate buffer for 10 minutes and rinsed
as well as stored in PBS. Subsequently, the sections were
incubated in normal goat serum for 1 hour, and then for
24 hours with primary antibodies against the specific
axonal marker PGP 9.5 (pre-diluted mouse anti-human
monoclonal antibody, ABCAM Inc, Cambridge, England;
ab75447) and antibodies against the 5-HT3A receptors
(goat polyclonal anti-human antibody, 1:100, Santa Cruz
Biotechnology Inc, Santa Cruz, CA, USA; sc-19150)
and NaV1.8 sodium channels (rabbit anti-human poly-
clonal antibody, 1:200, ABCAM Inc, Cambridge, Eng-
land; ab66743). The specificity of the antibodies has
been previously confirmed by pre-adsorption [36,37].
Sections were rinsed with PBS and incubated with
fluorescent secondary antibodies (Alexa 488 donkey-
anti-goat, 1:700 for 5HT3A, Alexa 555 donkey-anti-mouse,
1:700 for PGP9.5, and Alexa 633 donkey-anti-rabbit, 1:700
for NaV1.8, Vancouver, Canada). Sections were examined
with a Leica TCS SPE Confocal Microscope (Leica micro-
systems, Wetzlar, Germany) and images were captured for
analysis using a Leica scanner attached to the microscope
(Figure 1). Omission of the primary antibodies did not
result in specific staining of tested sections.Analyzes of the muscle biopsies and criteria for delineation
of one nerve fiber
From each muscle biopsy a median of 4 (IQR 1) sections
were analyzed.
Labeling was considered positive when the intensity of
the fluorescent signal exceeded the 95% confidence
interval of the mean background intensity. The mini-
mum length of a labeled fiber accepted was 1 μm.
When presenting the localization of the nerve fibers
they were divided into two groups, either associated with
myocytes or with connective tissue. When the PGP 9.5
positive nerve fibers were in close vicinity to myocytes, i.e.
long, tubular well-defined cells, they were placed in the
group associated with myocytes (“arrows” in Figure 2).
When the fibers were in irregular tissue surrounding the
myocytes they were grouped as associated with connective
tissue (“double arrows” in Figure 2).
Figure 1 Example of high power (40 x) photomicrographs for a masseter section from one female patient with myofascial TMD and a
healthy age- and sex-matched pain-free volunteer. The fibers shown are positively labelled for PGP 9.5 (A), 5-HT3A (B), and NaV1.8 (C). (D) is
the composite image. Calibration bar: 100 μm.
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sing the amount of PGP 9.5 labeled nerve fibers that co-
expressed the 5-HT3A receptor alone or in combination
with the NaV1.8 sodium channel. PGP 9.5 positive nerve fi-
bers that co-expressed both NaV1.8 and 5-HT3A receptors
were considered as putative nociceptors. The image pro-
cessing and analysis program ImageJ, (Image ProcessingFigure 2 A low power (10 x) (in A) and a high power (40 x) (in B) ima
pain-free volunteer). A. The arrows indicate individual muscle fascicles co
power (40 x, rounded square in A) image of PGP 9.5 labelling with exampl
(double arrows). The insets show examples of a PGP 9.5 positive fiber assoc
A: 100 μm, B: 25 μm.and Analysis in Java; National Institutes of Health, USA)
was used.
Statistics
For data and statistical analyses the SigmaStat software
version 3.10 (Systat software Inc., San Jose, CA, USA)
was used. Data concerning the participants are expressedge of the same section of a masseter muscle (microbiopsy from a
mposed of myocytes separated by connective tissue. B. A higher
es of fibers associated with myocytes (arrows) and connective tissue
iated with a myocyte (i) and with connective tissue (ii). Calibration bar
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expressed with median and interquartile range (IQR)
since they were either not normally distributed or
assessed on an interval scale. Data regarding receptor
expression was normally distributed and was not trans-
formed. The frequencies of receptor expression are pre-
sented as mean (±SEM). To test for significant differences
regarding the frequency of expression of the 5-HT3A
receptors and the NaV1.8 sodium channels as well as for
significant differences between biopsy techniques Students
t-tests were used. For all tests the level of significance was
set to P < .05.
Results
Receptor expression
Microbiopsies
In microbiopsies of healthy volunteers PGP 9.5 immuno-
reactive fibers were identified in sections from 12 sub-
jects (6 men and 6 women) of the masseter muscle and
from 14 subjects (7 men and 7 women) of the tibialis
muscle. In the masseter muscle an average of 8.2 ± 1.2
(mean ± SEM) PGP 9.5 immunoreactive fibers per sec-
tion was found and in the tibialis muscle an average of
7.8 ± 1.3 fibers per section was found. Most fibers that
showed PGP 9.5 immunoreactivity were associated with
myocytes (masseter = 68.4%, tibialis = 87.8%).
The frequency of PGP 9.5 fibers expressing the 5-
HT3A receptor alone or in combination with the NaV1.8
sodium channel are presented in Table 2, mean frequen-
cies for antibody labelling of PGP 9.5 immunoreactive fi-
bers are shown in Figure 3. Both in the masseter and
tibialis muscles, the majority of the PGP 9.5 positive
fibers expressed 5-HT3A receptors. In the tibialis muscle
a significantly greater number of these fibers wereTable 2 Presentation of the frequency (%) and location of the
Fibers expressing 5-HT3A
Percentage of
PGP 9.5 fibers
Location of positive f
Myocytes Connectiv
Traditional biopsies
Masseter muscle
Patients (n = 5) 98.3% 65.6% 34.4
Healthy (n = 5) 96.0% 62.5% 37.5
Microbiopsies
Masseter muscle
Healthy (n = 12) 85.2% 70.5% 29.5
Tibialis muscle
Healthy (n = 14) 88.7% 86.0% 14.0
The table shows the frequency of the PGP 9.5 immunoreactive fibers expressing th
well as the location of the positive fibers within the muscle tissue and their distribu
the myocytes).
*Significantly lower frequency of positive fibers in connective tissue compared to m
***Significantly higher frequency of positive fibers in connective tissue compared to
###Significantly greater frequency in patients than in healthy individuals (P < .001, uassociated with myocytes than with connective tissue
(Table 2).
In the masseter and tibialis muscles respectively, 8.2%
and 9.6% of PGP 9.5 positive fibers co-expressed NaV1.8
and 5-HT3A. The vast majority of these fibers were
found in connective tissue both in the masseter and in
the tibialis muscles.Sex differences
In the masseter there was no significant difference in the
mean nerve fiber density when men were compared with
women. There was no significant difference in the ex-
pression of 5-HT3A positive fibers associated with myo-
cytes or connective tissue between sexes (Table 3).
There was no significant difference in the mean dens-
ity of fibers in the tibialis when men were compared
with women. Likewise, there was no significant differ-
ence in the expression of 5-HT3A positive fibers associ-
ated with myocytes or with connective tissue (Table 3).Traditional biopsies of the masseter muscle
In the traditional masseter biopsies of healthy female
volunteers (n = 5) an average of 2.7 ± 0.2 PGP 9.5 immu-
noreactive nerve fibers per section was found.
The vast majority of the PGP 9.5 positive fibers
expressed 5-HT3A receptors. Similar to what was found
for the microbiopsies of the masseter muscle, the majority
of nerve fibers were associated with myocytes (Table 2).
12.0% of the PGP 9.5 positive fibers were found to co-
express NaV1.8 and 5-HT3A receptors. A significantly
greater number of nerve fibers that co-expressed NaV1.8
and 5-HT3A was associated with connective tissue than
with myocytes (Table 2).positive PGP 9.5 immunoreactive fibers
Fibers expressing 5-HT3A and NaV1.8
ibers Percentage of
PGP 9.5 fibers
Location of positive fibers
e tissue Myocytes Connective tissue
% 42.6%### 17.8% 82.2%***
% 12.0% 12.5% 87.5%***
% 8.2% 11.8% 88.2%***
%* 9.6% 0% 100.0%***
e 5-HT3A-receptor alone or in combination with the NaV1.8 sodium channel as
tion (in association with myocytes or in the connective tissue surrounding
yocytes (P < .011, paired t-test).
in myocytes (P < .001, paired t-test).
npaired t-test).
Figure 3 A comparison showing the different mean frequencies for antibody labelling on PGP 9.5 immunoreactive fibers (5-HT3A; both
5-HT3A and NaV1.8) in the masseter and tibialis tissues. There were no significant differences in the frequency of fibers that expressed 5-HT3A
or both 5-HT3A and NaV1.8, when the two muscles were compared (P > .05, Students t-test). Each bar represents the average from all the sections
obtained from each muscle type. The error bars depict standard error of the mean.
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average of 3.8 ± 3 PGP 9.5 positive fibers per section was
found. Virtually all PGP 9.5 positive fibers expressed 5-
HT3A receptors. Similar to healthy individuals, the major-
ity of these nerve fibers were associated with myocytes.
42.6% of the PGP 9.5 positive fibers in the masseter of
the patients co-expressed NaV1.8 and 5-HT3A receptors.
There was a significantly higher co-expression of NaV1.8
and 5-HT3A positive fibers that were associated with
connective tissue than with myocytes (Table 2).
Differences between TMD patients and pain-free controls
The total number of PGP 9.5 positive fibers per section
that expressed 5-HT3A receptors was significantly higher
in female patients (3.79 ± 0.75) compared to healthy fe-
males (2.37 ± 0.58) (P = .010). Also the frequency of PGPTable 3 Presentation of the mean (±SD) nerve fiber density a
Fibers per section (n=)
Men Women
Microbiopsies
Masseter muscle
Healthy (n = 12) 6.7 ± 1.8 5.6 ± 1.5
Tibialis muscle
Healthy (n = 14) 6.7 ± 1.9 8.9 ± 1.9
The table presents the mean nerve fiber density (i.e. fibers per section), the percent
(either in association with myocytes or in the connective tissue surrounding the my
There are microbiopsies from the masseter muscle from six men and six women, w
tibialis muscle.
There were no significant differences.9.5 positive fibers that co-expressed NaV1.8 and 5-HT3A
receptors was significantly higher than that found in
healthy women (Table 2; and as an example see
Figure 1).
Differences between the biopsy techniques
Both techniques provided an adequate muscle section.
However, the muscle sections obtained with the micro-
biopsy technique were significantly smaller in volume
and in weight as well as in the area of the wound at the
entrance to the muscle. Further, the microbiopsies
caused less discomfort and fewer visits for the individual
undergoing the procedure (Table 4).
The number of PGP 9.5 positive fibers per section
was significantly higher in the microbiopsies of healthy
women than in traditional biopsies from the healthynd their distribution within the sections
Nerve fiber density
Location (%) of positive fibers
Myocytes Connective tissue
Men Women Men Women
76 ± 15% 78 ± 20% 45 ± 20% 40 ± 24%
95 ± 2% 77 ± 13% 26 ± 17% 38 ± 17%
age difference of positive fibers within the muscle tissue, and the distribution
ocytes).
hile there are microbiopsies from seven men and seven women from the
Table 4 Comparison of the two techniques used for obtaining masseter biopsies from healthy volunteers
Microbiopsies (n = 18) Traditional biopsies (n = 10)
Mean weight of each muscle section 19.8 (±2.5) mg*** 58.4 (±9.6) mg
Mean volume of each muscle section 13.0 (±1.6) mm3*** 64.4 (±9.9) mm3
Surrounding tissues No Yes
Type of tissue Parotid gland (20%)
Fat cells (30%)
Adequate muscle section 100% 100%
Number of PGP 9.5 positive fibers
per section
8.2 ± 1.2* 2.7 ± 0.2
Area of wound 1 (±0.04) mm2*** 10 (±0.7) mm2
Post-surgical discomfort 3 (±1) days 8 (±2) days
Type of discomfort Palpatory tenderness over the belly of the masseter (100%) Palpatory tenderness over the belly of the
masseter muscle (100%)
Bleeding (6%) Limited jaw function (10%)
Chewing difficulties (50%)
Discomfort from sutures (100%)
Extra visit to remove sutures (100%)
Differences are presented as mean (±SD) values.
*P < .05, unpaired t-test, ***P < .001, unpaired t-test.
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ences in the receptor expression between the two biopsy
techniques. In the microbiopsy group, 70.5% of the fibers
associated with myocytes expressed 5-HT3A receptors
while the corresponding number was 62.5% in the trad-
itional biopsy group. Further 29.5% of the fibers associ-
ated with connective tissue fibers expressed 5-HT3A
receptors in the microbiopsy group, whereas the corre-
sponding number was 37.5% in the traditional biopsy
group (Table 2).
Discussion
Main findings
The main findings of this study were that the 5-HT3A re-
ceptor is highly expressed in human masseter and tibialis
muscle tissue, but that there were no differences in ex-
pression due to sex. Further, there were more immuno-
reactive nerve fibers expressing 5-HT3 receptors and
NaV1.8 sodium channels in the masseter muscle of fe-
male patients with myofascial TMD compared to healthy
female controls. These findings indicate that 5-HT3 re-
ceptors might be up-regulated in myofascial TMD and
may therefore play a role in pain transmission, hence
providing the 5-HT3-receptor as a target for future ther-
apeutics or as a potential biomarker of chronic muscle
pain.
Secondarily, the results from this study indicate that
the microbiopsy technique provided sufficient muscle
tissue, less discomfort and post-surgical pain than the
traditional biopsy technique. Therefore, the microbiopsy
technique can be regarded as a valid biopsy method forimmunohistochemical analyses of muscle tissue, and
may, thus, be preferred to traditional open biopsies in
future studies or even as a diagnostic tool.
Receptor expression
The immunohistochemical analysis of the muscle sections
indicates that the 5-HT3A receptor is highly expressed by
human masseter and tibialis anterior muscle nerve fibers.
To our knowledge there are no other studies that have
studied the expression of the 5-HT3 receptor in human
muscle tissues. A recent study did show that the NMDA
receptor is also expressed by masseter muscle nerve fibers
(45-50%) in humans and rats [22]. However, results from
animal studies regarding the expression of the 5-HT3 re-
ceptor in trigeminal and dorsal root ganglion neurons
[7,38] are consistent with the present study. It is well
established that the NaV1.8 sodium channels play an im-
portant role in nociception and chronic pain when found
on small unmyelinated and thinly myelinated sensory neu-
rons [24,25,29,30,39] since they contribute to action po-
tentials in sensory neurons [28,39,40] and are involved in
peripheral sensitization [23]. They have further also been
found in large diameter sensory neurons in human pain
states [41], as well as large diameter fibers in mouse [42]
and rat [26,43]muscle afferent neurons. Hence, this TTX
resistant sodium channel is not just limited to small diam-
eter nerve fibers [44]. Inflammation has been shown to
enhance nociceptive signaling by the NaV1.8 sodium chan-
nels [31,44-46], in part, through release of inflammatory
mediators, such as 5-HT and prostaglandin E2, which
directly increase NaV1.8 mediated currents [31,47].
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the peripheral level, acting on the 5-HT3 receptors,
which mainly appear on afferent nociceptive sensory,
autonomic and enteric neurons [16]. Given this, one can
assume that the NaV1.8 positive fibers are sensory neu-
rons with a potential nociceptive function, consequently
implying that the muscle nerve fibers that co-express the
5-HT3A receptors and NaV1.8 sodium channels are most
probably nociceptors.
Noteworthy is the significantly higher average of fibers
per section in the masseter muscle of patients with myo-
fascial TMD, which could indicate a proliferation of
nerve fibers in the painful muscle tissue. There is some
evidence that hyper-innervation of the tendon with puta-
tive nociceptive fibers occurs in Achilles tendinosis
[48,49]. The larger number of fibers in tender regions of
the masseter muscle of TMD patients found in this
study could indicate an up-regulation of 5-HT3 recep-
tors. This finding may explain previous findings that a
local injection of the 5-HT3 receptor antagonist granise-
tron was effective in decreasing muscle sensitivity in pa-
tients with localized myalgia [21] and fibromyalgia [50].
The majority of the 5-HT3A and NaV1.8 positive fibers
in the masseter muscle were found in the connective tis-
sue, which suggests that masticatory muscle pain may
emanate primarily from the connective tissue. This the-
ory is based on the findings from the muscle sections
where both the patients and healthy subjects had signifi-
cantly more NaV1.8 positive nerve fibers in connective
tissue compared to fibers associated with myocytes. The
elevated levels of serotonin in the masseter muscle in
patients with myofascial TMD [3] and the very high ex-
pression of 5-HT3A and NaV1.8 positive fibers on sen-
sory nerves associated with connective tissue, shown in
this study, support the theory that the muscle nocicep-
tors in painful muscles could be sensitized by serotonin
and hence that serotonin may have an important role in
myofascial TMD.
Apart from pain mediation, the 5-HT3 receptors are
involved in many events in the human body. Centrally
they play an important role in psychosis, anxiety, cogni-
tion and eating disorders [51], but also in motor system
function. A recent study showed that activation of the
5-HT3 receptor induced rhythmic movements of the hin-
dlimbs in mice [52]. In the periphery they have a well-
known role in emetic pathways [53] and they have a role
in the intestinal tone, activating colonic migrating motor
complex, i.e. muscular motor activity [54]. PGP 9.5
labels both small and large diameter myelinated fibers
[55] and NaV1.8 is a marker of small diameter thinly
myelinated nociceptive fibers [44]. With this in mind, as
the majority of the 5-HT3A positive muscle nerve fibers
were located near myocytes and did not co-express
NaV1.8, our findings imply that the 5-HT3A positive fibersin association with the myocytes are likely either proprio-
ceptive muscle spindle afferent fibers or motor axons [56].
Comparison of the biopsy techniques
The results of this study indicate that the microbiopsy
technique provided sufficient muscle tissue for immuno-
histochemistry and led to less discomfort and post-
surgical pain as well as fewer visits than the traditional
biopsy technique. This is in agreement with a previous
study comparing the microbiopsy technique with the
traditional open biopsy technique in the vastus lateralis
of the quadriceps femoris muscle [57]. Further, the
microbiopsy technique seems to be more precise, since
by using the Bard®TruGuide™ coaxial needle, the surgeon
is more likely to remove tissue from the exact region of
interest without damaging the surrounding tissue [35]. It
was also shown that the muscle sections from the micro-
biopsies contained less of the surrounding tissues, such as
parts of the salivary glands than traditional open biopsies
(Table 4). Taken together this shows that the microbiopsy
technique is a valid biopsy method for immunohistochem-
ical analyses of muscle tissue and hence, may be preferred
to traditional open biopsies in future studies or even as a
diagnostic tool.
Differences due to sex or anatomical localization
In contrast to a previous study [7] indicating that the ex-
pression of 5-HT3 receptors by trigeminal ganglion neu-
rons innervating the masseter muscle was higher in
female rats, this study showed no significant difference
in the expression of 5-HT3A receptors in the masseter or
tibialis muscles, when men and women were compared.
In previous studies, women reported more pain than
men when serotonin was injected into the masseter
muscle [13], and a larger pain area when hypertonic sa-
line was injected [10]. Based on those studies one could
have expected a significant sex difference with a larger
amount of nerve fibers co-expressing 5-HT3A receptors
and NaV1.8 sodium channels in women. Further, a previ-
ous human experimental study showed that systemic ad-
ministration of the 5-HT3 receptor antagonist granisetron
increased the PPT over the tibialis anterior muscle in men
but not in women [11]. As a possible explanation for this
difference could have been that the number of receptors
differs between men and women, however, the findings of
the present study do not support this explanation. It
should be noted that a limitation of this study is the small
sample size (6–7 individuals of each sex), which may have
been insufficient to permit identification of sex-related dif-
ferences in 5-HT3A receptor expression.
There was a difference between the two skeletal mus-
cles since a majority of the fibers co-expressing 5-HT3A
receptors and NaV1.8 sodium channels were found in
the connective tissue in the masseter muscle while in
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ated with myocytes. The tibialis muscle is rarely exposed
to chronic pain in contrast to the masseter muscle and
is further innervated by the deep peroneal nerve which
major role is to contract the muscle fibers in order to
dorsiflex and invert the foot [58]. In contrast to the tibi-
alis anterior muscle, the masseter muscle expressed a
larger amount of putatively nociceptive nerve fibers in
the connective tissue. This is an interesting difference
between muscles that could be a consequence of the dif-
ferent innervation with either trigeminal branches (mas-
seter muscle) or spinal branches (tibialis muscle) and
functionality of the nerves regarding motor and sensory
functions [58]. Therefore, the larger amount of puta-
tively nociceptive nerve fibers in the connective tissue of
the masseter muscle and the difference in innervation
might partly explain the more frequent presence of
chronic myalgia in the masseter muscle.
Study limitations
One limitation of the study is, as mentioned, the small
sample size which might have affected the outcome re-
garding sex-related differences. Another possible limita-
tion of the study is the exclusion criterion “use of
analgesic or anti-inflammatory medication during the
24 hours preceding the biopsy”. This criterion was primar-
ily in order to avoid any risk of including a patient with
myofascial TMD among the healthy participants. How-
ever, 24 hours is a short wash-out period for NSAIDs
which could have affected the biopsy procedure negatively,
for example through increased bleeding, since the use of
NSAIDs might impair the thrombocyte aggregation for up
to 8–10 days. Use of NSAID might also have suppressed
receptor expression. If so, it is likely that patients with
myfascial TMD would have been affected more and in
that case the difference in frequency would be even
greater than found in the current study. The storage of
the biopsies in paraffin could be another possible limita-
tion since this technique might blunt the antigenicity of
the samples, which may make it more difficult to detect
the receptors. In future studies the muscle biopsies are
suggested to be frozen immediately in −80°C.
Conclusions
This study showed that the 5-HT3A receptor is highly
expressed by human masseter and tibialis muscle nerve
fibers. Further, a greater number of putative nociceptors
were found to express the 5-HT3 in the masseter muscle
of female patients with myofascial TMD compared to
healthy female controls, which suggests that 5-HT3 re-
ceptors might be up-regulated in myofascial TMD. This
finding could support the use of 5-HT3 receptor expres-
sion in muscle biopsies as a biomarker of chronic masti-
catory muscle pain.Abbreviations
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